This special issue of Palliative Medicine aspires to build bridges between haematology and palliative care, as well as contribute to dissemination of knowledge about the complexity of issues related to palliative care in haematological malignancies and the haematological problems in patients receiving palliative care.
Fortunately, in palliative care in haematological malignancies, we increasingly observe exchange of information and an approach of mutual understanding. Manitta et al., 1 9 years ago, described different barriers that could hamper the collaboration between haematology and palliative care and proposed potential solutions to improve this collaboration. In our understanding, one of the most valuable pieces of advice to follow is 'Referral (to palliative care) should be based on needs rather than life expectancy'. Others have reiterated this advice more recently. 2 Recent literature reinforces the message that focusing palliative care on poor prognostic and expected shortsurvival patients with haematological malignancies is not welcomed by haematologists, and it is recognized as one of the greatest barriers for palliative care in haematology. 3 , 4 New strategies based on patients' needs are advocated. 5 , 6 This needs-based premise raises many issues which need to be discussed when attempting to implement referrals to palliative care. These issues include who, how and when the patients' and their relatives' needs should be identified.
In some way, responding to these questions is linked with the model of cooperation proposed. LeBlanc et al., 7 discussing potential models for early palliative care in haematology, commented on the positive experiences of a 'trigger-based' model for patients admitted to undergo stem cell transplantation 8 , 9 and the potential benefit of a 'co-rounding model' in inpatients, based on the experience published in non-haematological patients. 10 Another model postulated is the 'incorporation' into the haematology department of a specific haematology palliative care team, 11 based on the need of a better understanding and approach of the distinctive aspects of haematological malignancies. Other models that we can designate as 'cooperative' are based on early patients' and relatives' needs assessment and close cooperation with the haematology team, allowing mutual understanding and learning. 12 In this special issue, Elise Button, in the invited editorial, discusses in detail the relevant aspects to better understanding a 'concurrent' palliative care model in haematological malignancies.
Considering the different approaches and models suggested to overcome the barriers between palliative care and haematology, this probably means that a single palliative care model does not exist, and palliative care teams should be very adaptive to gain access to patients, maybe including, in addition to the chosen model, the denomination of the consult team as supportive care instead of palliative care as it has been suggested and insist on mutual educative programmes. 6 As the papers on integration of haemato-oncology and palliative care illustrate, the shift in attitudes and needs is a gradual one which is facilitated by the changing natural history of some malignancies, a more 'supportive' focus earlier in the disease and drivers such as family expectations. The prominence of cancer-associated thrombosis within palliative care continues on a similarly indolent journey. Rather than representing a change in attitudes within the specialty, it more likely reflects an acknowledgement of the increased incidence of venous thromboembolism among our patients and the challenges therein. As cancer care has progressed, patients are living longer with metastatic disease and continue to receive systemic anti-cancer therapies until later in life. Increased age, metastatic disease and systemic anti-cancer therapies are all independent risk factors for the development of cancer-associated thrombosis, and it should be no surprise that as the use of chemotherapy has increased, so too has the incidence of cancer-associated thrombosis in parallel. Particular challenges prevail for palliative care teams with respect to cancer-associated thrombosis, including the role of thromboprophylaxis in our patient group and how the introduction of the direct-acting oral anticoagulants should impact on patient care. The papers by Cai et al. 13 and Hutchinson et al., 14 in this special edition, consider these issues admirably, adding new perspective and data to a growing field of interest.
We are heartened by the response of readers to contribute to this special edition of an arguably niche subject which may have gained less interest 10 years ago. To Haematology and palliative care: the needs are out there 840604P MJ0010.1177/0269216319840604Palliative MedicineEditorial editorial2019 Editorial preside such a breadth of topics has been a privilege for us. Such a diversity of papers, from an authorship covering three continents, not only illustrates the universal importance of haemato-oncology in palliative care but also the true international reach of Palliative Medicine as a publication.
